GlobalData: Thermo Fisher to be major player in COVID-19 diagnostic tests following acquisition of Qiagen

Thermo Fisher Scientific is expected to produce millions of coronavirus (COVID-19) diagnostic tests following the acquisition of Qiagen for an approximate transaction value of US$11.5bn per share, says GlobalData, a leading data and analytics company.

GlobalData: Thermo Fisher to be major player in COVID-19 diagnostic tests following acquisition of Qiagen

Qiagen, a provider of molecular diagnostics and sample preparation technologies, offers a long list of nucleic acid amplification tests (NAATs) for the diagnosis and monitoring of infectious and genetic diseases, including real-time reverse-transcription (RT-PCR), which is currently being used to diagnose COVID-19.

Dara Lo, Medical Devices Analyst at GlobalData comments:

NAATs are highly used for the screening, confirmation, and monitoring of many infectious and genetic diseases due to their high sensitivity and accuracy. This is reflected in the human papilloma virus (HPV) tests market where NAATs are expected to be worth over US$371m, globally, by 2028 with Qiagen holding a significant percentage of the market share.

With a multi-million-dollar market in HPV NAATs, which contributes to 4.7% of all cancers world-wide, GlobalData expects an even larger market share for COVID-19, which can have up to 70% prevalence globally.”

Source:

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Thermo Fisher Scientific Inc.. (2020, March 20). GlobalData: Thermo Fisher to be major player in COVID-19 diagnostic tests following acquisition of Qiagen. News-Medical. Retrieved on April 25, 2024 from https://www.news-medical.net/news/20200320/GlobalData-Thermo-Fisher-to-be-major-player-in-COVID-19-diagnostic-tests-following-acquisition-of-Qiagen.aspx.

  • MLA

    Thermo Fisher Scientific Inc.. "GlobalData: Thermo Fisher to be major player in COVID-19 diagnostic tests following acquisition of Qiagen". News-Medical. 25 April 2024. <https://www.news-medical.net/news/20200320/GlobalData-Thermo-Fisher-to-be-major-player-in-COVID-19-diagnostic-tests-following-acquisition-of-Qiagen.aspx>.

  • Chicago

    Thermo Fisher Scientific Inc.. "GlobalData: Thermo Fisher to be major player in COVID-19 diagnostic tests following acquisition of Qiagen". News-Medical. https://www.news-medical.net/news/20200320/GlobalData-Thermo-Fisher-to-be-major-player-in-COVID-19-diagnostic-tests-following-acquisition-of-Qiagen.aspx. (accessed April 25, 2024).

  • Harvard

    Thermo Fisher Scientific Inc.. 2020. GlobalData: Thermo Fisher to be major player in COVID-19 diagnostic tests following acquisition of Qiagen. News-Medical, viewed 25 April 2024, https://www.news-medical.net/news/20200320/GlobalData-Thermo-Fisher-to-be-major-player-in-COVID-19-diagnostic-tests-following-acquisition-of-Qiagen.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Thermo Fisher Scientific continues to support the development of COVID-19 vaccines, therapies